Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience
Articles > Article · 2018
Authors: Ayse UYSAL, Nur AKAD SOYER, Melda Ozkan, Fahri ŞAHİN, Filiz VURAL, Mahmut TÖBÜ, Murat TOMBULOĞLU, Güray SAYDAM
TURKISH JOURNAL OF MEDICAL SCIENCES, Journal Indexed in SCI Expanded, International, 2018, vol 48, pp 80-83
DOI: 10.3906/sag-1611-97
Summary
Background/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone.